Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Pharmaceuticals Division Core operating profit growth driven by patent settlement 2022 CHFm % sales 2022 vs. 2021 CER growth Sales 22,347 100 3% Royalties & other op. inc. 1,918 8.6 41% Cost of sales -4,430 -19.8 14% COGS+PC: +9% M&D -3,096 -13.9 4% R & D -5,729 -25.6 -3% G & A -692 -3.1 -8% Core operating profit 10,318 46.2 8% +8% in CHF CER-Constant Exchange Rates; COGS=costs of goods sold; PC-period costs Roche 19

View entire presentation